{
  "ticker": "ARWR",
  "name": "Arrowhead Pharmaceuticals",
  "description": "Clinical-stage biopharmaceutical company developing RNAi therapeutics using its proprietary TRiM platform. First approved RNAi therapeutic (REDEMPLO) in Nov 2025. 19 programs across cardiometabolic, pulmonary, hepatic, CNS, and oncology.",
  "sector": "Biotechnology",
  "website": "https://arrowheadpharma.com",
  "lead_asset": "Plozasiran",
  "lead_asset_stage": "Approved (FCS) / Phase 3 (sHTG)",
  "lead_asset_indication": "Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia",
  "financials": {
    "market_cap": "$7.65B",
    "market_cap_value": 7650000000,
    "cash_position": "$920M+",
    "cash_pro_forma": "$1.32B (pro forma)",
    "enterprise_value": "$6.3B",
    "shares_outstanding": "121.2M",
    "as_of": "2026-02-03"
  },
  "key_catalyst": {
    "event": "Plozasiran sHTG Phase 3 PDUFA",
    "expected_date": "Q3 2026",
    "significance": "10x larger market than approved FCS indication (~500K US patients)"
  },
  "programs": [
    {
      "name": "Plozasiran (ARO-APOC3)",
      "aliases": [
        "ARO-APOC3",
        "REDEMPLO"
      ],
      "target": "APOC3",
      "stage": "Approved (FCS) / Phase 3 (sHTG)",
      "indication": "FCS, Severe Hypertriglyceridemia, Mixed Hyperlipidemia",
      "partner": "Amgen",
      "key_data": "80% TG reduction (PALISADE), 83% pancreatitis risk reduction",
      "next_catalyst": "sHTG approval (PDUFA)",
      "fda_verification": {
        "is_approved": true,
        "verified_at": "2026-02-02T19:48:06.401973Z",
        "approval_date": "2025-11-18",
        "brand_name": "REDEMPLO",
        "sponsor": "ARROWHEAD",
        "application_number": "NDA219947",
        "indication_summary": "1 INDICATIONS AND USAGE REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is an apolipoprotein C-III ( apoC-III )-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycer"
      },
      "satya_view": {
        "bull_thesis": "First-in-class RNAi therapeutic for APOC3 with best-in-class 80% triglyceride reduction and durable quarterly dosing. FCS approval validates mechanism. sHTG represents 10x larger market (~500K US patients). SHASTA-3/4/5 trials ongoing for broader indications. Amgen partnership provides experienced CV sales force.",
        "bear_thesis": "FCS is tiny orphan market (~3,000 US patients). sHTG faces competition from Ionis olezarsen. Amgen controls commercialization meaning majority economics flow to partner. No CV outcomes data yet.",
        "key_question": "Will Phase 3 sHTG trials (SHASTA-3/4/5) succeed and enable broad commercial launch in the much larger sHTG population?"
      },
      "mechanism": {
        "modality": "RNAi (siRNA)",
        "delivery": "GalNAc conjugate (TRiM platform) - hepatocyte-targeted",
        "description": "Silences APOC3 mRNA in hepatocytes. APOC3 inhibits lipoprotein lipase. By reducing APOC3, plozasiran increases LPL activity, accelerating clearance of triglyceride-rich lipoproteins.",
        "dosing": "Subcutaneous injection every 12 weeks (quarterly)"
      },
      "clinical_data": [
        {
          "trial_name": "PALISADE",
          "nct_id": "NCT05089084",
          "phase": "Phase 3",
          "indication": "Familial Chylomicronemia Syndrome (FCS)",
          "status": "ACTIVE_NOT_RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT05089084",
          "design": {
            "n_enrolled": 75,
            "arms": [
              "Plozasiran 50mg Q12W",
              "Placebo"
            ],
            "duration": "10 weeks (primary), 1-year OLE",
            "primary_endpoint": "Percent change in fasting TG at Week 10",
            "enrollment_verified": true
          },
          "results": {
            "primary": {
              "endpoint": "TG reduction at Week 10",
              "result": "-80%",
              "comparator": "Placebo: -18%",
              "p_value": "<0.001"
            },
            "key_secondary": [
              {
                "endpoint": "Pancreatitis risk reduction",
                "result": "83%"
              },
              {
                "endpoint": "Patients achieving TG <750 mg/dL",
                "result": "88%",
                "comparator": "Placebo: 8%"
              }
            ]
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:08.911644Z",
            "official_title": "A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "phase": "Phase 3",
            "enrollment": 75,
            "enrollment_type": "actual",
            "primary_completion_date": "2024-04-29",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT05089084"
          }
        },
        {
          "trial_name": "SHASTA-2",
          "nct_id": "NCT04720534",
          "phase": "Phase 2",
          "indication": "Severe Hypertriglyceridemia (sHTG)",
          "status": "COMPLETED",
          "source_url": "https://clinicaltrials.gov/study/NCT04720534",
          "design": {
            "n_enrolled": 229,
            "arms": [
              "Plozasiran 50mg Q24W",
              "Plozasiran 50mg Q12W",
              "Placebo"
            ],
            "duration": "24 weeks",
            "primary_endpoint": "Percent change in fasting TG at Week 24"
          },
          "results": {
            "primary": {
              "endpoint": "TG reduction at Week 24",
              "result": "-77% (Q12W)",
              "comparator": "Placebo: +4%",
              "p_value": "<0.001"
            }
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:08.944032Z",
            "official_title": "A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia",
            "overall_status": "COMPLETED",
            "phase": "Phase 2",
            "enrollment": 229,
            "enrollment_type": "actual",
            "primary_completion_date": "2023-03-09",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT04720534"
          }
        },
        {
          "trial_name": "SHASTA-3",
          "nct_id": "NCT06347003",
          "phase": "Phase 3",
          "indication": "Severe Hypertriglyceridemia (sHTG)",
          "status": "ACTIVE_NOT_RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT06347003",
          "design": {
            "primary_endpoint": "Percent change in fasting TG",
            "n_enrolled": 446,
            "enrollment_verified": true
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:08.977062Z",
            "official_title": "Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "phase": "Phase 3",
            "enrollment": 446,
            "enrollment_type": "actual",
            "primary_completion_date": "2026-06",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT06347003"
          }
        },
        {
          "trial_name": "SHASTA-4",
          "nct_id": "NCT06347016",
          "phase": "Phase 3",
          "indication": "Severe Hypertriglyceridemia (sHTG)",
          "status": "ACTIVE_NOT_RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT06347016",
          "design": {
            "primary_endpoint": "Percent change in fasting TG",
            "n_enrolled": 311,
            "enrollment_verified": true
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.008746Z",
            "official_title": "Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "phase": "Phase 3",
            "enrollment": 311,
            "enrollment_type": "actual",
            "primary_completion_date": "2026-06",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT06347016"
          }
        },
        {
          "trial_name": "SHASTA-5",
          "nct_id": "NCT06880770",
          "phase": "Phase 3",
          "indication": "Severe Hypertriglyceridemia at Risk of Acute Pancreatitis",
          "status": "RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT06880770",
          "design": {
            "primary_endpoint": "Acute pancreatitis events",
            "n_enrolled": 288,
            "enrollment_verified": true
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.042431Z",
            "official_title": "Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)",
            "overall_status": "RECRUITING",
            "phase": "Phase 3",
            "enrollment": 288,
            "enrollment_type": "estimated",
            "primary_completion_date": "2029-03",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT06880770"
          }
        },
        {
          "trial_name": "SHASTA-10",
          "nct_id": "NCT06822790",
          "phase": "Phase 3",
          "indication": "Long-term safety/efficacy in Hypertriglyceridemia",
          "status": "RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT06822790",
          "design": {
            "primary_endpoint": "Long-term safety",
            "n_enrolled": 869,
            "enrollment_verified": true
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.075768Z",
            "official_title": "A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)",
            "overall_status": "RECRUITING",
            "phase": "Phase 3",
            "enrollment": 869,
            "enrollment_type": "estimated",
            "primary_completion_date": "2028-07",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT06822790"
          }
        },
        {
          "trial_name": "MUIR",
          "nct_id": "NCT04998201",
          "phase": "Phase 2",
          "indication": "Mixed Hyperlipidemia",
          "status": "COMPLETED",
          "source_url": "https://clinicaltrials.gov/study/NCT04998201",
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.109873Z",
            "official_title": "A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia",
            "overall_status": "COMPLETED",
            "phase": "Phase 2",
            "enrollment": 353,
            "enrollment_type": "actual",
            "primary_completion_date": "2023-02-10",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT04998201"
          }
        },
        {
          "trial_name": "MUIR-3",
          "nct_id": "NCT06347133",
          "phase": "Phase 3",
          "indication": "Hypertriglyceridemia",
          "status": "ACTIVE_NOT_RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT06347133",
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.141546Z",
            "official_title": "Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "phase": "Phase 3",
            "enrollment": 1456,
            "enrollment_type": "actual",
            "primary_completion_date": "2026-05",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT06347133"
          }
        }
      ],
      "competitors": [
        {
          "drug_name": "Volanesorsen (Waylivra)",
          "company": "Ionis/Sobi",
          "mechanism": "ASO targeting APOC3",
          "stage": "Approved (EU only)",
          "efficacy": "77% TG reduction",
          "differentiation": "Plozasiran has better safety (no platelet issues), less frequent dosing (quarterly vs weekly)"
        },
        {
          "drug_name": "Olezarsen",
          "company": "Ionis",
          "mechanism": "GalNAc-ASO targeting APOC3",
          "stage": "Approved (US, Dec 2024)",
          "efficacy": "~60% TG reduction",
          "differentiation": "Both quarterly. Plozasiran shows higher TG reduction. Commercial race ongoing."
        }
      ],
      "catalysts": [
        {
          "event": "FCS approval (FDA)",
          "expected_date": "2025-11-18",
          "actual_date": "2025-11-18",
          "status": "completed",
          "outcome": "Approved as REDEMPLO",
          "fda_verified": true
        },
        {
          "event": "sHTG approval decision (PDUFA)",
          "expected_date": "H1 2026",
          "status": "upcoming",
          "significance": "10x larger market than FCS"
        },
        {
          "event": "SHASTA-3 topline data",
          "status": "upcoming"
        },
        {
          "event": "SHASTA-4 topline data",
          "status": "upcoming"
        }
      ],
      "partnership": {
        "partner": "Amgen",
        "established": "2016",
        "programs_covered": [
          "Plozasiran",
          "Zodasiran"
        ],
        "financial_terms": {
          "upfront": 35000000,
          "milestones_potential": 617000000,
          "royalties": "Tiered, low double-digit",
          "received_to_date": 120000000
        }
      }
    },
    {
      "name": "Zodasiran (ARO-ANG3)",
      "aliases": [
        "ARO-ANG3"
      ],
      "target": "ANGPTL3",
      "stage": "Phase 2/3",
      "indication": "Mixed Dyslipidemia, HoFH, ASCVD Risk Reduction",
      "partner": "Amgen",
      "key_data": "65% LDL-C reduction, 70% TG reduction",
      "next_catalyst": "Phase 3 HoFH data",
      "fda_verification": {
        "is_approved": false,
        "verified_at": "2026-02-02T19:48:06.993700Z",
        "raw_results_count": 0
      },
      "satya_view": {
        "bull_thesis": "ANGPTL3 is genetically validated - LOF mutations show low LDL, low TGs, reduced CV events. Zodasiran achieves dual LDL-C (65%) and TG (70%) reduction with quarterly dosing. Phase 3 HoFH trial recruiting.",
        "bear_thesis": "Crowded lipid market with statins and PCSK9i. Evinacumab (Regeneron) already approved for HoFH. Quarterly injection vs daily statin limits adoption.",
        "key_question": "Can zodasiran demonstrate CV outcomes benefit to justify premium pricing?"
      },
      "mechanism": {
        "modality": "RNAi (siRNA)",
        "delivery": "GalNAc conjugate (TRiM platform)",
        "description": "Silences ANGPTL3 which inhibits both LPL and endothelial lipase. Lowers both TG and LDL-C.",
        "dosing": "Subcutaneous Q12W (quarterly)"
      },
      "clinical_data": [
        {
          "trial_name": "ARCHES-2",
          "nct_id": "NCT04832971",
          "phase": "Phase 2",
          "indication": "Mixed Dyslipidemia",
          "status": "COMPLETED",
          "source_url": "https://clinicaltrials.gov/study/NCT04832971",
          "design": {
            "n_enrolled": 204
          },
          "results": {
            "primary": {
              "endpoint": "Non-HDL-C reduction",
              "result": "-55%",
              "p_value": "<0.001"
            },
            "key_secondary": [
              {
                "endpoint": "LDL-C reduction",
                "result": "-65%"
              },
              {
                "endpoint": "TG reduction",
                "result": "-70%"
              }
            ]
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.181249Z",
            "official_title": "A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia",
            "overall_status": "COMPLETED",
            "phase": "Phase 2",
            "enrollment": 204,
            "enrollment_type": "actual",
            "primary_completion_date": "2022-08-30",
            "has_results": true,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT04832971"
          }
        },
        {
          "trial_name": "Gateway",
          "nct_id": "NCT05217667",
          "phase": "Phase 2",
          "indication": "Homozygous Familial Hypercholesterolemia (HoFH)",
          "status": "ACTIVE_NOT_RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT05217667",
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.206883Z",
            "official_title": "Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "phase": "Phase 2",
            "enrollment": 18,
            "enrollment_type": "actual",
            "primary_completion_date": "2023-05-02",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT05217667"
          }
        },
        {
          "trial_name": "Zodasiran Phase 3 HoFH",
          "nct_id": "NCT07037771",
          "phase": "Phase 3",
          "indication": "Homozygous Familial Hypercholesterolemia",
          "status": "RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT07037771",
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.240055Z",
            "official_title": "Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)",
            "overall_status": "RECRUITING",
            "phase": "Phase 3",
            "enrollment": 60,
            "enrollment_type": "estimated",
            "primary_completion_date": "2027-08-20",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT07037771"
          }
        }
      ],
      "competitors": [
        {
          "drug_name": "Evinacumab (Evkeeza)",
          "company": "Regeneron",
          "mechanism": "ANGPTL3 antibody",
          "stage": "Approved (HoFH)",
          "efficacy": "47% LDL-C reduction",
          "differentiation": "Zodasiran shows higher efficacy (65% vs 47%), quarterly SC vs monthly IV"
        }
      ],
      "catalysts": [
        {
          "event": "Phase 3 HoFH initiated",
          "actual_date": "2024",
          "status": "completed"
        },
        {
          "event": "Phase 3 HoFH data",
          "expected_date": "2026-2027",
          "status": "upcoming"
        }
      ]
    },
    {
      "name": "Fazirsiran (ARO-AAT)",
      "aliases": [
        "ARO-AAT",
        "TAK-999"
      ],
      "target": "AAT (Alpha-1 Antitrypsin)",
      "stage": "Phase 3",
      "indication": "Alpha-1 Antitrypsin Deficiency Liver Disease (AATD-LD)",
      "partner": "Takeda",
      "key_data": "96% Z-AAT reduction, liver fibrosis improvement",
      "next_catalyst": "Phase 3 data 2026+",
      "fda_verification": {
        "is_approved": false,
        "verified_at": "2026-02-02T19:48:07.574100Z",
        "raw_results_count": 0
      },
      "satya_view": {
        "bull_thesis": "Fazirsiran addresses root cause of AATD liver disease by silencing mutant Z-AAT that aggregates in hepatocytes. Phase 2 showed 96% reduction with histological fibrosis improvement. No approved therapy exists. Takeda partnership provides $1B+ potential milestones.",
        "bear_thesis": "AATD liver disease is rare (~10-15% of AATD patients). Regulatory path unclear - may require clinical outcomes not just Z-AAT reduction. Takeda controls development.",
        "key_question": "Will Phase 3 SEQUOIA show sufficient fibrosis improvement for FDA approval?"
      },
      "mechanism": {
        "modality": "RNAi (siRNA)",
        "delivery": "GalNAc conjugate (TRiM platform)",
        "description": "Silences AAT mRNA, reducing both normal and mutant Z-AAT. Prevents accumulation of toxic aggregates in hepatocytes.",
        "dosing": "Subcutaneous Q12W (quarterly)"
      },
      "clinical_data": [
        {
          "trial_name": "AROAAT-2002",
          "nct_id": "NCT03946449",
          "phase": "Phase 2",
          "indication": "AATD Liver Disease",
          "status": "COMPLETED",
          "source_url": "https://clinicaltrials.gov/study/NCT03946449",
          "design": {
            "n_enrolled": 16
          },
          "results": {
            "primary": {
              "endpoint": "Hepatic Z-AAT reduction",
              "result": "-96%",
              "p_value": "<0.001"
            },
            "key_secondary": [
              {
                "endpoint": "Liver fibrosis improvement",
                "result": "7/8 patients improved"
              }
            ]
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.272507Z",
            "official_title": "A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)",
            "overall_status": "COMPLETED",
            "phase": "Phase 2",
            "enrollment": 16,
            "enrollment_type": "actual",
            "primary_completion_date": "2022-04-28",
            "has_results": true,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT03946449"
          }
        },
        {
          "trial_name": "SEQUOIA Phase 2",
          "nct_id": "NCT03945292",
          "phase": "Phase 2",
          "indication": "AATD Liver Disease",
          "status": "COMPLETED",
          "source_url": "https://clinicaltrials.gov/study/NCT03945292",
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.312866Z",
            "official_title": "A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]",
            "overall_status": "COMPLETED",
            "phase": "Phase 2",
            "enrollment": 40,
            "enrollment_type": "actual",
            "primary_completion_date": "2021-11-08",
            "has_results": true,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT03945292"
          }
        },
        {
          "trial_name": "SEQUOIA Phase 3",
          "nct_id": "NCT05677971",
          "phase": "Phase 3",
          "indication": "AATD Liver Disease with Fibrosis",
          "status": "RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT05677971",
          "sponsor": "Takeda",
          "design": {
            "n_enrolled": 160,
            "primary_endpoint": "Fibrosis improvement without worsening",
            "primary_completion_date": "2028-02"
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.340419Z",
            "official_title": "A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis",
            "overall_status": "RECRUITING",
            "phase": "Phase 3",
            "enrollment": 160,
            "enrollment_type": "estimated",
            "primary_completion_date": "2028-02-17",
            "has_results": false,
            "sponsor": "Takeda",
            "url": "https://clinicaltrials.gov/study/NCT05677971"
          }
        },
        {
          "trial_name": "SEQUOIA Extension",
          "nct_id": "NCT05899673",
          "phase": "Phase 3",
          "indication": "Long-term safety",
          "status": "ACTIVE_NOT_RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT05899673",
          "sponsor": "Takeda",
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.377518Z",
            "official_title": "A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "phase": "Phase 3",
            "enrollment": 31,
            "enrollment_type": "actual",
            "primary_completion_date": "2033-05-02",
            "has_results": false,
            "sponsor": "Takeda",
            "url": "https://clinicaltrials.gov/study/NCT05899673"
          }
        }
      ],
      "partnership": {
        "partner": "Takeda",
        "established": "2020",
        "financial_terms": {
          "upfront": 300000000,
          "milestones_potential": 1040000000,
          "royalties": "Tiered on net sales",
          "received_to_date": 340000000
        }
      }
    },
    {
      "name": "ARO-INHBE",
      "aliases": [],
      "target": "INHBE (Inhibin beta E)",
      "stage": "Phase 1/2",
      "indication": "Obesity, Metabolic Dysfunction",
      "partner": null,
      "key_data": "6-9% weight loss (Phase 1)",
      "next_catalyst": "Phase 1/2 data 2025-2026",
      "fda_verification": {
        "is_approved": false,
        "verified_at": "2026-02-02T19:48:08.224821Z",
        "raw_results_count": 0
      },
      "satya_view": {
        "bull_thesis": "Novel genetically-validated obesity target. INHBE LOF mutations associated with lower BMI. Early data shows 6-9% weight loss with quarterly dosing and no GI side effects (unlike GLP-1s). ARWR retains full rights.",
        "bear_thesis": "GLP-1s achieving 15-25% weight loss are becoming standard of care. 6-9% may not be competitive. Mechanism less understood than GLP-1.",
        "key_question": "Can ARO-INHBE achieve >15% weight loss to compete with GLP-1 agonists?"
      },
      "mechanism": {
        "modality": "RNAi (siRNA)",
        "delivery": "GalNAc conjugate (TRiM platform)",
        "description": "Silences INHBE which forms activin E. Activin E signals through ALK7 to promote fat accumulation. Blocking this shifts energy balance toward fat oxidation.",
        "dosing": "Subcutaneous Q12W (quarterly)"
      },
      "clinical_data": [
        {
          "trial_name": "ARO-INHBE Phase 1/2",
          "nct_id": "NCT06700538",
          "phase": "Phase 1/2",
          "indication": "Obesity with and without Type 2 Diabetes",
          "status": "RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT06700538",
          "design": {
            "primary_endpoint": "Safety, percent change in body weight",
            "n_enrolled": 120,
            "enrollment_verified": true
          },
          "results": {
            "primary": {
              "endpoint": "Body weight reduction (preliminary)",
              "result": "-6 to -9%",
              "comparator": "Placebo: -1%"
            }
          },
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.405182Z",
            "official_title": "A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus",
            "overall_status": "RECRUITING",
            "phase": "Phase 1",
            "enrollment": 120,
            "enrollment_type": "estimated",
            "primary_completion_date": "2026-05",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT06700538"
          }
        }
      ],
      "competitors": [
        {
          "drug_name": "Semaglutide (Wegovy)",
          "company": "Novo Nordisk",
          "mechanism": "GLP-1 agonist",
          "stage": "Approved",
          "efficacy": "15-17% weight loss",
          "differentiation": "ARO-INHBE is quarterly vs weekly, no GI side effects"
        },
        {
          "drug_name": "Tirzepatide (Zepbound)",
          "company": "Eli Lilly",
          "mechanism": "GLP-1/GIP dual agonist",
          "stage": "Approved",
          "efficacy": "20-25% weight loss",
          "differentiation": "Tirzepatide best-in-class efficacy"
        }
      ]
    },
    {
      "name": "ARO-ALK7",
      "aliases": [],
      "target": "ALK7 (ACVR1C)",
      "stage": "Phase 1/2",
      "indication": "Obesity, Metabolic Dysfunction",
      "partner": null,
      "key_data": "Preclinical: significant weight loss in NHPs",
      "next_catalyst": "Phase 1/2 data",
      "fda_verification": {
        "is_approved": false,
        "verified_at": "2026-02-02T19:48:08.844373Z",
        "raw_results_count": 0
      },
      "satya_view": {
        "bull_thesis": "ALK7 is receptor for INHBE/activin E - orthogonal approach to same pathway. Dual program gives optionality. Earlier stage means less dilution if successful.",
        "bear_thesis": "Even earlier stage than ARO-INHBE. Same GLP-1 competition. May be redundant with ARO-INHBE.",
        "key_question": "Will ALK7 inhibition show differentiated profile vs ARO-INHBE?"
      },
      "mechanism": {
        "modality": "RNAi (siRNA)",
        "delivery": "GalNAc conjugate (TRiM platform)",
        "description": "Silences ALK7 receptor in adipose tissue. ALK7 mediates activin E signaling that promotes fat accumulation.",
        "dosing": "Subcutaneous (interval TBD)"
      },
      "clinical_data": [
        {
          "trial_name": "ARO-ALK7 Phase 1/2",
          "nct_id": "NCT06937203",
          "phase": "Phase 1/2",
          "indication": "Obesity with and without Type 2 Diabetes",
          "status": "RECRUITING",
          "source_url": "https://clinicaltrials.gov/study/NCT06937203",
          "ctgov_verification": {
            "verified_at": "2026-02-02T19:48:09.437289Z",
            "official_title": "A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus",
            "overall_status": "RECRUITING",
            "phase": "Phase 1",
            "enrollment": 126,
            "enrollment_type": "estimated",
            "primary_completion_date": "2026-07",
            "has_results": false,
            "sponsor": "Arrowhead Pharmaceuticals",
            "url": "https://clinicaltrials.gov/study/NCT06937203"
          }
        }
      ]
    }
  ],
  "partnerships": [
    {
      "partner": "Amgen",
      "established": "2016",
      "status": "Active",
      "programs": [
        "Plozasiran",
        "Zodasiran"
      ],
      "financial_terms": {
        "upfront": 35000000,
        "milestones_potential": 617000000,
        "royalties": "Tiered, low double-digit",
        "received_to_date": 120000000
      }
    },
    {
      "partner": "Takeda",
      "established": "2020",
      "status": "Active",
      "programs": [
        "Fazirsiran"
      ],
      "financial_terms": {
        "upfront": 300000000,
        "milestones_potential": 1040000000,
        "royalties": "Tiered on net sales",
        "received_to_date": 340000000
      }
    },
    {
      "partner": "Johnson & Johnson (Janssen)",
      "established": "2018",
      "status": "Active",
      "programs": [
        "JNJ-3989 (ARO-HBV)",
        "JNJ-75220795 (ARO-HBV2)"
      ],
      "financial_terms": {
        "upfront": 250000000,
        "milestones_potential": 1600000000,
        "royalties": "Mid-single to low-double digit",
        "received_to_date": 375000000
      }
    }
  ],
  "company_catalysts": [
    {
      "event": "Plozasiran FCS approval",
      "actual_date": "2025-11-18",
      "status": "completed",
      "outcome": "Approved as REDEMPLO",
      "fda_verified": true
    },
    {
      "event": "Plozasiran sHTG PDUFA",
      "expected_date": "H1 2026",
      "status": "upcoming",
      "significance": "10x larger market opportunity"
    },
    {
      "event": "SHASTA-3/4/5 Phase 3 data",
      "expected_date": "2026",
      "status": "upcoming"
    },
    {
      "event": "Zodasiran Phase 3 HoFH data",
      "expected_date": "2026-2027",
      "status": "upcoming"
    },
    {
      "event": "SEQUOIA Phase 3 data",
      "expected_date": "2028",
      "status": "upcoming"
    }
  ],
  "_data_verification": {
    "last_verified": "2026-02-02T19:30:00Z",
    "sources": {
      "fda_approvals": "OpenFDA API (https://api.fda.gov/drug/drugsfda.json)",
      "clinical_trials": "ClinicalTrials.gov API v2 (https://clinicaltrials.gov/api/v2/studies)",
      "company_info": "Company website, SEC filings"
    },
    "nct_ids_verified": [
      "NCT05089084",
      "NCT04720534",
      "NCT06347003",
      "NCT06347016",
      "NCT06880770",
      "NCT06822790",
      "NCT04998201",
      "NCT06347133",
      "NCT04832971",
      "NCT05217667",
      "NCT07037771",
      "NCT03946449",
      "NCT03945292",
      "NCT05677971",
      "NCT05899673",
      "NCT06700538",
      "NCT06937203"
    ]
  },
  "ir_news": {
    "scraped_at": "2026-02-02T19:48:09.437314Z",
    "errors": [
      "Request error: HTTPSConnectionPool(host='ir.arrowheadpharma.com', port=443): Read timed out. (read timeout=30)"
    ],
    "items": []
  },
  "_refresh": {
    "last_refreshed": "2026-02-02T19:48:39.694968Z",
    "sources_checked": [
      "OpenFDA",
      "ClinicalTrials.gov",
      "IR News"
    ],
    "changes_made": 0,
    "change_summary": {
      "fda_updates": 0,
      "trial_status_changes": 0,
      "enrollment_updates": 0,
      "news_catalysts_found": 0
    }
  }
}